Clinical trial · Observational
Gonadal Toxicity in Women With Hodgkin Lymphoma
Observational Retrospective Study to Evaluate the Incidence of the Gonadal Toxicity in Women of Reproductive Age With Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Gruppo Italiano Studio Linfomi has been collecting data on patients with Hodgkin Lymphoma (HL) since 1988. This archive represents a homogeneous series of consecutive patients with HL. The very long follow up and the availability of clinical and treatment data make it feasible to perform a study on the gonadal toxicity related to treatment for HL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- women with hodgkin lymphoma treated with chemotherapy
Primary outcomes (1)
- measure
- incidence of gonadal toxicity in terms of irreversible amenorrhea and infertility, in women of reproductive age with Hodgkin lymphoma treated with chemotherapy.
- timeFrame
- from end of treatment until date of last contact/visit
Secondary outcomes (1)
- measure
- role of a prophylactic treatment with oral contraceptives and GnRH analogs in preventing gonadal damage
- timeFrame
- from end of treatment until date of last contact/visit
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients in complete remission after chemotherapy for Hodgkin lymphoma * Age ≥ 18 e \< 40 years * Previous regular menstrual cycle * No previous or concomitant gynecological diseases affecting reproducing function * No other chemo-radiotherapy for other neoplasm * Written informed consent Exclusion Criteria: * none
References
Publications (0)
Data not yet available